

Company Announcement
ASX: HPC

DATE: 10/5/2024

Issue of Shares

Hydration solutions company **The Hydration Pharmaceuticals Company Limited (ASX: HPC)** (“Hydralyte” or “the Company”) advises that today, it has issued 39,771,269 fully paid ordinary shares in the Company (“Shares”) to PURE Asset Management Pty Ltd as trustee for The Income and Growth Fund (“PURE”) and their nominees in satisfaction of the Company’s requirement to prepay PURE an amount of interest equal to \$742,500 (**Interest Prepayment Amount**) under the terms of the Amended Pure Facility as set out in the ASX announcement dated 27 March 2024.

The Shares have been issued under the Company’s Listing Rule 7.1 capacity. The balance of the Interest Prepayment Amount, being \$213,867, that is not able to be satisfied via the issue of Shares has been capitalised.

The Company also confirms that, further to the ASX announcement dated 26 April 2024, the Company has drawn down the Third Loan of \$1.7 million available under the Amended Pure Facility.

Cleansing Statement

The Company hereby gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) (Act) that:

1. on 10 May 2024 the Company completed the issue and allotment of 39,771,269 Shares;
2. the Company issued the Shares without disclosure to investors under Part 6D.2 of the Act;
3. as at the date of this notice, the Company has complied with:
 - a. the provisions of Chapter 2M of the Act as they apply to the Company; and
 - b. sections 674 and 674A of the Act; and
4. as at the date of this notice there is no ‘excluded information’ (as that term is defined in section 708A(7) and (8) of the Act).

An Appendix 2A in relation to the Shares will be lodged separately today.

ENDS

This announcement was authorised for release by the Board of HydraLyte.

For further information:

Investors/Media

Henry Jordan
Six Degrees Investor Relations
0431 271 538
henry.jordan@sdir.com.au